Do analysts recommend CVAC or CYPH?

Cypherpunk Technologies has a consensus price target of $4.90, indicating a potential upside of 31.37%. Given Cypherpunk Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Cypherpunk Technologies is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, CRVS or CYPH?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.61 N/A Cypherpunk Technologies N/A N/A $4.82M $0.56 6.66

Is CRVS or CYPH more profitable?

Cypherpunk Technologies' return on equity of -20.76% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -36.15% -33.62% Cypherpunk Technologies N/A -20.76% -19.48%

Does the media refer more to CRVS or CYPH?

In the previous week, Cypherpunk Technologies had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 0.48 beat Cypherpunk Technologies' score of 0.28 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cypherpunk Technologies 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ALMS or CYPH?

In the previous week, Cypherpunk Technologies had 2 more articles in the media than Alumis. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 4 mentions for Alumis. Alumis' average media sentiment score of 0.48 beat Cypherpunk Technologies' score of 0.28 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cypherpunk Technologies 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CYPH or ABUS?

In the previous week, Cypherpunk Technologies had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.73 beat Cypherpunk Technologies' score of 0.28 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, CYPH or ANL?

Cypherpunk Technologies has higher earnings, but lower revenue than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M $0.56 6.66 Adlai Nortye $5M 213.81 -$35.53M N/A N/A

Is CYPH or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -20.76% -19.48% Adlai Nortye N/A N/A N/A

Does the media prefer CYPH or ANL?

In the previous week, Cypherpunk Technologies had 4 more articles in the media than Adlai Nortye. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat Cypherpunk Technologies' score of 0.28 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cypherpunk Technologies 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adlai Nortye 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cypherpunk Technologies (CYPH) Competitors

$3.73 +0.33 (+9.71%)

As of 04:00 PM Eastern

Compare

CYPH vs. CVAC, CRVS, ALMS, ABUS, and ANL

Should you buy Cypherpunk Technologies stock or one of its competitors? Cypherpunk Technologies's main competitors and comparable companies include CureVac (CVAC), Corvus Pharmaceuticals (CRVS), Alumis (ALMS), Arbutus Biopharma (ABUS), and Adlai Nortye (ANL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cypherpunk Technologies compare to CureVac?

CureVac (NASDAQ:CVAC) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

CureVac has a net margin of 199.92% compared to Cypherpunk Technologies' net margin of 0.00%. Cypherpunk Technologies' return on equity of -20.76% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

17.3% of CureVac shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cypherpunk Technologies has a consensus price target of $4.90, indicating a potential upside of 31.37%. Given Cypherpunk Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Cypherpunk Technologies is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cypherpunk Technologies had 6 more articles in the media than CureVac. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 0 mentions for CureVac. Cypherpunk Technologies' average media sentiment score of 0.28 beat CureVac's score of 0.00 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Cypherpunk Technologies	Neutral

CureVac has higher revenue and earnings than Cypherpunk Technologies. CureVac is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	6.66

CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Summary

Cypherpunk Technologies beats CureVac on 9 of the 15 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, Cypherpunk Technologies had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 0.48 beat Cypherpunk Technologies' score of 0.28 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cypherpunk Technologies	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	6.66

Corvus Pharmaceuticals presently has a consensus price target of $33.33, indicating a potential upside of 148.02%. Cypherpunk Technologies has a consensus price target of $4.90, indicating a potential upside of 31.37%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cypherpunk Technologies' return on equity of -20.76% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Corvus Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Summary

Corvus Pharmaceuticals beats Cypherpunk Technologies on 8 of the 14 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Alumis?

Alumis (NASDAQ:ALMS) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Cypherpunk Technologies has lower revenue, but higher earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	43.65	-$243.32M	-$3.86	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	6.66

In the previous week, Cypherpunk Technologies had 2 more articles in the media than Alumis. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 4 mentions for Alumis. Alumis' average media sentiment score of 0.48 beat Cypherpunk Technologies' score of 0.28 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cypherpunk Technologies	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.5% of Cypherpunk Technologies shares are owned by institutional investors. 33.7% of Alumis shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alumis presently has a consensus target price of $33.27, suggesting a potential upside of 310.27%. Cypherpunk Technologies has a consensus target price of $4.90, suggesting a potential upside of 31.37%. Given Alumis' stronger consensus rating and higher probable upside, research analysts plainly believe Alumis is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alumis has a beta of -0.81, meaning that its stock price is 181% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Cypherpunk Technologies has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Cypherpunk Technologies' return on equity of -20.76% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

Summary

Cypherpunk Technologies beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Arbutus Biopharma?

Cypherpunk Technologies (NASDAQ:CYPH) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Cypherpunk Technologies has higher earnings, but lower revenue than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	6.66
Arbutus Biopharma	$14.08M	70.49	-$33.50M	$0.79	6.34

Arbutus Biopharma has a net margin of 84.22% compared to Cypherpunk Technologies' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-20.76%	-19.48%
Arbutus Biopharma	84.22%	90.98%	82.34%

Cypherpunk Technologies has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cypherpunk Technologies presently has a consensus price target of $4.90, suggesting a potential upside of 31.37%. Arbutus Biopharma has a consensus price target of $5.00, suggesting a potential downside of 0.20%. Given Cypherpunk Technologies' higher possible upside, equities research analysts plainly believe Cypherpunk Technologies is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cypherpunk Technologies had 5 more articles in the media than Arbutus Biopharma. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.73 beat Cypherpunk Technologies' score of 0.28 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Arbutus Biopharma beats Cypherpunk Technologies on 10 of the 14 factors compared between the two stocks.

How does Cypherpunk Technologies compare to Adlai Nortye?

Cypherpunk Technologies (NASDAQ:CYPH) and Adlai Nortye (NASDAQ:ANL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

30.5% of Cypherpunk Technologies shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cypherpunk Technologies had 4 more articles in the media than Adlai Nortye. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.92 beat Cypherpunk Technologies' score of 0.28 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cypherpunk Technologies	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adlai Nortye	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cypherpunk Technologies has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Cypherpunk Technologies has higher earnings, but lower revenue than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	6.66
Adlai Nortye	$5M	213.81	-$35.53M	N/A	N/A

Cypherpunk Technologies currently has a consensus price target of $4.90, suggesting a potential upside of 31.37%. Adlai Nortye has a consensus price target of $29.50, suggesting a potential upside of 77.71%. Given Adlai Nortye's stronger consensus rating and higher possible upside, analysts plainly believe Adlai Nortye is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Adlai Nortye's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-20.76%	-19.48%
Adlai Nortye	N/A	N/A	N/A

Summary

Adlai Nortye beats Cypherpunk Technologies on 9 of the 12 factors compared between the two stocks.

Get Cypherpunk Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYPH vs. The Competition

Export

Metric	Cypherpunk Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$401.95M	$3.96B	$7.27B	$13.28B
Dividend Yield	N/A	3.64%	2.53%	12.80%
P/E Ratio	6.66	14.53	275.14	25.87
Price / Sales	N/A	1,369.25	683.81	116.52
Price / Cash	N/A	41.62	28.04	34.72
Price / Book	2.04	15.85	10.73	6.45
Net Income	$4.82M	-$22.82M	$3.49B	$360.08M
7 Day Performance	68.02%	1.94%	2.35%	2.34%
1 Month Performance	162.68%	-3.44%	-1.74%	-2.49%
1 Year Performance	1,112.22%	37.20%	17.91%	6.42%

Cypherpunk Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYPH Cypherpunk Technologies	2.979 of 5 stars	$3.73 +9.7%	$4.90 +31.4%	+1,073.2%	$401.95M	N/A	6.66	40	News Coverage Analyst Upgrade Gap Up High Trading Volume
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880	News Coverage
CRVS Corvus Pharmaceuticals	2.1893 of 5 stars	$12.55 +2.6%	$33.33 +165.6%	+111.6%	$1.03B	N/A	N/A	37	Positive News
ALMS Alumis	3.8386 of 5 stars	$7.82 -1.5%	$33.27 +325.5%	+89.4%	$1.03B	$7.40M	N/A	239
ABUS Arbutus Biopharma	1.4831 of 5 stars	$5.07 +0.4%	$5.00 -1.4%	+17.6%	$1.00B	$14.08M	6.42	19	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYPH) was last updated on 9/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. CVAC, CRVS, ALMS, ABUS, and ANL

How does Cypherpunk Technologies compare to CureVac?

Summary

How does Cypherpunk Technologies compare to Corvus Pharmaceuticals?

Summary

How does Cypherpunk Technologies compare to Alumis?

Summary

How does Cypherpunk Technologies compare to Arbutus Biopharma?

Summary

How does Cypherpunk Technologies compare to Adlai Nortye?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cypherpunk Technologies (CYPH) Competitors

CYPH vs. CVAC, CRVS, ALMS, ABUS, and ANL

How does Cypherpunk Technologies compare to CureVac?

Is CVAC or CYPH more profitable?

Do insiders & institutionals hold more shares of CVAC or CYPH?

Do analysts recommend CVAC or CYPH?

Does the media favor CVAC or CYPH?

Which has better valuation and earnings, CVAC or CYPH?

Which has more risk & volatility, CVAC or CYPH?

Summary

How does Cypherpunk Technologies compare to Corvus Pharmaceuticals?

Does the media refer more to CRVS or CYPH?

Which has preferable valuation & earnings, CRVS or CYPH?

Do analysts recommend CRVS or CYPH?

Is CRVS or CYPH more profitable?

Do institutionals & insiders believe in CRVS or CYPH?

Which has more volatility and risk, CRVS or CYPH?

Summary

How does Cypherpunk Technologies compare to Alumis?

Which has higher earnings and valuation, ALMS or CYPH?

Does the media favor ALMS or CYPH?

Do institutionals and insiders hold more shares of ALMS or CYPH?

Do analysts recommend ALMS or CYPH?

Which has more risk & volatility, ALMS or CYPH?

Is ALMS or CYPH more profitable?

Summary

How does Cypherpunk Technologies compare to Arbutus Biopharma?

Which has higher earnings & valuation, CYPH or ABUS?

Is CYPH or ABUS more profitable?

Which has more risk & volatility, CYPH or ABUS?

Do institutionals & insiders hold more shares of CYPH or ABUS?

Do analysts rate CYPH or ABUS?

Does the media prefer CYPH or ABUS?

Summary

How does Cypherpunk Technologies compare to Adlai Nortye?

Do institutionals and insiders have more ownership in CYPH or ANL?

Does the media prefer CYPH or ANL?

Which has more risk & volatility, CYPH or ANL?

Which has preferable valuation and earnings, CYPH or ANL?

Do analysts recommend CYPH or ANL?

Is CYPH or ANL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYPH vs. The Competition

Cypherpunk Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools